文献速递颈动脉与弓上血管

颈动脉经颈动脉血运重建中氯吡格雷与替格瑞洛抗血小板治疗的比较:血管外科学会血管质量倡议研究

Clopidogrel versus ticagrelor for antiplatelet therapy in transcarotid artery revascularization in the Society for Vascular Surgery Vascular Quality Initiative.
PubMed 文献 · J Vasc Surg · 2021-12-14

基于血管外科学会血管质量倡议数据库2015年1月至2021年3月接受颈动脉经颈动脉血运重建且围术期使用氯吡格雷或替格瑞洛的患者数据,比较两组30天卒中、大出血及卒中/心肌梗死/死亡复合结局。氯吡格雷组11973例、替格瑞洛组426例,替格瑞洛组合并冠状动脉疾病、不稳定型心绞痛或6个月内心肌梗死及胰岛素依赖型糖尿病比例更高;未校正及多因素校正和倾向评分匹配后,两组30天结局均无统计学显著差异。

要点

  • 替格瑞洛组较氯吡格雷组合并冠状动脉疾病比例更高(66% vs 51%,P < .001)。
  • 未校正30天卒中率替格瑞洛组0.5% vs 氯吡格雷组1.3%,差异无统计学意义(P = .14)。
  • 多因素校正和倾向评分匹配后两组30天卒中、大出血及复合结局仍无统计学显著差异。

核心结论

  • 在颈动脉经颈动脉血运重建患者中,尽管替格瑞洛组内科风险明显更高,替格瑞洛与氯吡格雷作为辅助抗血小板治疗的30天卒中、大出血及卒中/心肌梗死/死亡复合发生率相似。
  • 作者指出仍需随机前瞻性试验及更大样本量、更长随访的研究来更好地考察这两种药物在颈动脉经颈动脉血运重建中的结局差异。

研究设计与样本

  • 研究分析血管外科学会血管质量倡议数据库中2015年1月至2021年3月接受颈动脉经颈动脉血运重建、围术期抗血小板方案含氯吡格雷或替格瑞洛的患者数据并进行比较。
  • 采用多因素逻辑回归和倾向评分匹配评估30天主要结局:卒中、大出血事件及卒中/心肌梗死/死亡复合率,并校正患者基线特征。
  • 共11973例接受含氯吡格雷双联抗血小板治疗的颈动脉经颈动脉血运重建患者,对比426例含替格瑞洛者。

主要发现

  • 与氯吡格雷组相比,替格瑞洛组冠状动脉疾病比例更高(66% vs 51%,P < .001)。
  • 替格瑞洛组不稳定型心绞痛或6个月内心肌梗死比例更高(9% vs 3%,P < .001),胰岛素依赖型糖尿病比例更高(19% vs 14%,P < .001)。
  • 未校正30天卒中率替格瑞洛组0.5% vs 氯吡格雷组1.3%(P = .14),大出血率1.4% vs 2.4%(P = .18),卒中/心肌梗死/死亡复合率1.6% vs 1.9%(P = .71),均无统计学显著差异。
  • 多因素校正和倾向评分匹配后,上述30天结局仍无统计学显著差异。

局限性

  • 原文指出仍需随机前瞻性试验以及样本量更大、随访更长的研究来更好地考察这两种药物在颈动脉经颈动脉血运重建中的结局差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Transcarotid artery revascularization (TCAR) with dynamic flow reversal is a hybrid technique for operative management of carotid artery stenosis. Dual antiplatelet therapy is recommended for patients undergoing TCAR; however, nonresponders to these medications may be predisposed to perioperative thromboembolic complications. Prevalent in up to 44% to 66% of patients taking clopidogrel, high on-treatment platelet reactivity may thus be responsible for a portion of adverse cerebrovascular events in TCAR. A previous single-institution study has demonstrated the use of ticagrelor as a viable alternative to clopidogrel for antiplatelet therapy in patients undergoing TCAR; however, large-scale comparisons between clopidogrel and ticagrelor are needed to confirm the safety of ticagrelor outside of highly selected patients and providers. METHODS: Data from patients enrolled in the Society for Vascular Surgery Vascular Quality Initiative undergoing TCAR with a perioperative antiplatelet therapy regimen including either clopidogrel or ticagrelor from January 2015 to March 2021 were analyzed and compared. Multivariable logistic regression and propensity score matching were used to evaluate the primary 30-day outcomes of stroke, major bleeding event, and combined stroke/myocardial infarction (MI)/death rate while adjusting for baseline characteristics of the patients. RESULTS: A total of 11,973 patients underwent TCAR with a dual antiplatelet therapy regimen that included clopidogrel vs 426 patients with ticagrelor. Compared with patients on clopidogrel, patients on ticagrelor were significantly more likely to have coronary artery disease (51% vs 66%; P < .001), particularly unstable angina or MI within 6 months (3% vs 9%; P < .001), and more likely to have insulin-dependent diabetes mellitus (14% vs 19%; P < .001). The unadjusted 30-day rates of stroke, major bleeding, and combined stroke/MI/death were not statistically significant among both groups (1.3% vs 0.5%; P = .14, 2.4% vs 1.4%; P = .18, and 1.9% vs 1.6%; P = .71], respectively). After multivariable adjustment and propensity matching, these remained statistically insignificant. CONCLUSIONS: Despite a substantially higher medical risk in patients undergoing TCAR with ticagrelor, 30-day rates of stroke, major bleeding events, and combined stroke/MI/death were similar between patients on ticagrelor and clopidogrel as part of adjunctive antiplatelet therapy. Randomized prospective trials, and studies with larger sample sizes and longer follow-up will be needed to better examine the outcome differences in TCAR between these two medications.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Ghamraoui AK, Chang H, Maldonado TS, et al. Clopidogrel versus ticagrelor for antiplatelet therapy in transcarotid artery revascularization in the Society for Vascular Surgery Vascular Quality Initiative. J Vasc Surg. 2021. PMID: 34920001. doi:10.1016/j.jvs.2021.11.060

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。